TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07680790: A Phase III, Randomized, Open-label Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy as First-Lin

Sponsor: Bristol-Myers Squibb · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 850 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$787,248

Rescue Site Savings

+$524,832

Unlock Full NCT07680790 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07680790 Rescue Dossier →